Evidence map›Paper›PMID 41612409›Full record

ArticleThe international journal of behavioral nutrition and physical activity2026

Vigorous intermittent lifestyle physical activity (VILPA) and mortality risk among US adults: a wearables-based national cohort study.

Nicholas A Koemel, Matthew N Ahmadi, Raaj Kishore Biswas, Cecilie Thøgersen-Ntoumani, Armando Teixeira-Pinto, Clara K Chow, Jaroslaw Harezlak, Emmanuel Stamatakis

Abstract read
In one paragraph

Article in The international journal of behavioral nutrition and physical activity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicholas A KoemelMackenzie Wearables Research Hub, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Matthew N AhmadiMackenzie Wearables Research Hub, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Raaj Kishore BiswasMackenzie Wearables Research Hub, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Cecilie Thøgersen-NtoumaniDepartment of Sports Science and Clinical Biomechanics, Danish Centre for Motivation and Behaviour Science (DRIVEN), University of Southern Denmark, Odense, Denmark.
Armando Teixeira-PintoSchool of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Clara K ChowDepartment of Cardiology, Westmead Applied Research Centre, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.
Jaroslaw HarezlakDepartment of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN, United States of America.
Emmanuel StamatakisMackenzie Wearables Research Hub, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia. emmanuel.stamatakis@sydney.edu.au.

Funding

National Health and Medical Research Council Investigator Grant (APP 1194510)
6 · The paper itself

Abstract

backgroundVigorous intermittent lifestyle physical activity (VILPA) completed through normal daily living may offer a time-efficient avenue to accrue physical activity in a behaviourally sustainable manner. However, no research to date has explored its association with mortality in a nationally representative population. This study aimed to examine the dose-response association between VILPA and mortality risk in a nationally representative sample of US adults.

methodsThis study included a nationally representative sample of 3293 US adults from the 2011-14 National Health and Nutrition Examination Survey (NHANES) who self-reported no participation in structured exercise (52.3% female; mean age: 50.7 [SD: 16.6 years]. The dose-response relationship between VILPA and all-cause mortality was estimated using multivariable-adjusted cubic splines. Average daily frequency (bouts/day) and duration (minutes/day) of VILPA bouts lasting up to one minute were measured using a wrist-worn accelerometer.

resultsOver the mean (SD) 6.7 (1.4) year follow-up period, 290 all-cause mortality events occurred. Compared to the referent point (0 bouts per day), there was an L-shaped dose-response association where the median frequency (5.3 bouts per day) was associated with a 44% lower risk of all-cause mortality (HR: 0.56; 95% CI: 0.39, 0.82). The dose response curve was less steep beyond approximately 8 bouts per day (HR: 0.46; 95% CI: 0.28, 0.77). Findings for the median frequency of VILPA bouts (5.3 bouts per day) remained consistent after excluding participants with poor health (HR: 0.51: 95% CI: 0.29, 0.87) and those who completed no VILPA (HR: 0.57: 95% CI: 0.38, 0.86). When excluding adults with prevalent cardiovascular disease or cancer at baseline (n = 2,731, 152 events), the dose-response relationship was similar, although the 95% CIs crossed unity for most of the curve (e.g. median frequency of VILPA bouts HR: 0.68: 95% CI: 0.41, 1.11).

conclusionsIn a nationally representative sample of US adults, short bursts of intermittent vigorous physical activity were associated with a lower risk of mortality. Excluding those with prevalent cardiovascular disease and cancer led to attenuated dose-response curves and wider confidence intervals, suggesting that the observed relationships may, at least partly, be driven by existing disease-induced reverse causation. While these results highlight some potential of VILPA as a time-efficient source of activity, additional observational studies with longer follow up and larger sample sizes are warranted.

Indexed as

ExerciseLife StyleMortalityAccelerometryAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedNutrition SurveysRisk FactorsUnited StatesAll-cause mortalityLifestyle physical activityMachine learning

Identifiers

PMID41612409
PMCPMC12952009

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.